Oncology

Latest News

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

By Jared Kaltwasser

May 7th 2025

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

By Hayden E. Klein

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com

COA 2025: Insight, Innovation, and Independent Strength

By Maggie L. Shaw

May 5th 2025

Community Oncology Reacts to Trump's Drug Pricing Executive Order

By Maggie L. Shaw

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com

5 Things You Should Know About Skin Cancer

By Pearl Steinzor

May 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 2nd 2018

Cost of Care

Various presenters at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia discussed the cost of care involved in several different cancer treatments.

February 1st 2018

New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study

Surabhi Dangi-Garimella, PhD

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

February 1st 2018

Ibrutinib Is More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia

Jaime Rosenberg

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

February 1st 2018

E-Cigarette Smoke Poses Threat to DNA Repair Activity

Kaitlynn Ely

E-cigarette smokers have a high risk of developing lung and bladder cancer, as well as certain heart diseases due to carcinogenic e-cigarette smoke (ECS), according to a study published in the Proceedings of the National Academy of Sciences.

February 1st 2018

Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care

Surabhi Dangi-Garimella, PhD

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

February 1st 2018

Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH

Surabhi Dangi-Garimella, PhD

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

February 1st 2018

AJMC®tv Interviews, January 2018

At the American Society of Hematology’s 59th Annual Meeting and Exposition, healthcare industry leaders sat down with The American Journal of Managed Care® to speak about what’s new and important about changes in healthcare. Access the video clips at ajmc.com/conferences/ash-2017.

February 1st 2018

Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being

Surabhi Dangi-Garimella, PhD

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

February 1st 2018

Biosimilars Update

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

January 31st 2018

CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients

Surabhi Dangi-Garimella, PhD

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

January 31st 2018

Study Shows Interactive Tool Increases Patient Knowledge of Breast Cancer Treatment Options

Samantha DiGrande

The Cancer Surveillance and Outcomes Research Team at the University of Michigan Comprehensive Cancer Center recently developed an interactive online tool to help patients with breast cancer understand their treatment options more fully.

January 31st 2018

Dr Roger Brito on When Providers Should Be Involved in Reimbursement Model Development

Providers should be involved in new reimbursement model development from day 1, said Roger Brito, DO, national director for oncology, Aetna.

January 31st 2018

CAR T-Cell Therapy Named ASCO's Advance of the Year

Jaime Rosenberg

Chimeric antigen receptor (CAR) T-cell therapy has been named the Advance of the Year in ASCO’s Clinical Cancer Advances 2018. According to the annual report, CAR T-cell therapy is “poised to transform the outlook for children and adults with certain otherwise incurable cancers."

January 30th 2018

Analysis Shows Majority of Hospitals Will See Payment Increases Despite 340B Payment Cuts

Jaime Rosenberg

As a result of the Medicare Outpatient Prospective Payment System rule that took effect on January 1, 85% of 340B hospitals will see net payment increases in 2018. Rural hospitals will reap the largest benefits, according to an analysis conducted by Avalere and commissioned by Community Oncology Alliance.

January 30th 2018

Nat Turner: Data Can Disrupt Clinical Research and Improve Patient Care

Nat Turner, co-founder and CEO of Flatiron Health, explains how data can be used for finding potential patients to be included in clinical trials.

January 30th 2018

Scientists Develop Tool to Analyze Links Between Lifestyle Choices and Certain Cancers

Kaitlynn Ely

A team of 20 scientists in the fields of informatics, statistics, epidemiology, systematic reviews, cancer biology, and nutrition have developed a tool that will assess the links in published human studies between lifestyle factors and cancer.

January 30th 2018

Using Health IT to Increase Medication Adherence and Enhance Precision Medicine

Jaime Rosenberg

As health information technology (IT) tools are continually being introduced into the healthcare sphere, organizations are utilizing these tools to optimize care coordination, patient experience, and patient outcomes. Today, 2 organizations join us; 1 uses a 2-way text messaging platform to support patients and increase medication adherence, and the other is teaming up with a pharmaceutical company to develop health IT solutions in order to enhance precision medicine in oncology.

January 29th 2018

Oncologists Overcome Hurdles to Deliver Cancer Care in Puerto Rico

Allison Inserro

Even though much more remains to be done on an island where half of its US residents still lack power, the situation is improving for cancer patients in Puerto Rico, doctors and organizations said recently in interviews with The American Journal of Managed Care®. In Puerto Rico, more than 75% of the cancer care is delivered in the community, not hospitals.

January 29th 2018

Dr Mark Fendrick: How Expensive Therapies Fit Into VBID for Oncology

When a drug becomes first-line, I would like to think that as a clinician I would have access to that, but most importantly that my patients would not have to have a bake sale or take out a second mortgage on their homes to get therapies that are designed specifically for them, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.

January 28th 2018

ASCO Provides CMS Recommendations on Revisions to Part D

Kaitlynn Ely

The American Society of Clinical Oncology (ASCO) recommends that CMS guard cancer patients from high out-of-pocket costs that will impede patient access to life-extending cancer drugs, according to the society’s comments regarding proposed financial revisions to the Medicare Prescription Drug Benefit Program (Part D).

January 27th 2018

Gut Microbiome Diversity Associated With Blood Infections in Pediatric Patients With Cancer

Laura Joszt, MA

Every year, central lines are associated with causing blood infections in an estimated 400,000 patients with cancer. However, new research has found that changes in the microbiome may be responsible for some or many of the infections usually attributed to central lines.

January 27th 2018

Bo Gamble Explains How COA Helps Practices Prepare for OCM

Bo Gamble, director of Strategic Practice Initiatives at the Community Oncology Alliance (COA), explains how COA plays a role in supporting practices in preparing for Oncology Care Model.

January 26th 2018

Via Oncology Acquisition Positions Pathway Provider for Growth

Mary Caffrey

Via Pathways covers more than 2000 different patient representations in cancer care.

January 26th 2018

Study Notes Racial Differences in Risk of Recurrence Among Patients With Breast Cancer

Kaitlynn Ely

Non-Hispanic black women diagnosed with HER2-negative, lymph node-negative breast cancer who had recurrence score testing had higher estimated risks of distant recurrence than their non-Hispanic white counterparts.

January 25th 2018

High Cost Sharing Associated With Reduced Access to Targeted Therapies for Patients With mRCC

Jaime Rosenberg

High cost sharing is associated with reduced and/or delayed access to targeted therapies under Medicare Part D for patients with metastatic renal cell carcinoma, suggesting that financial barriers play a significant role in treatment decisions, according to a study published in Cancer Medicine.

January 24th 2018

Patients Prefer End-of-Life Care in Their Location of Choice

Kaitlynn Ely

Patients diagnosed with cancer want their doctors to ask them their desire location for end-of-life (EOL) care, according to a recent study published in the Journal of the National Comprehensive Cancer Network.

January 24th 2018

Dr Peter Aran on What Oncologists Implementing OCM Can Learn From Existing Models

Over the next years, these spheres (ACOs, primary care, and oncology) that are going on in CMMI need to be coalesced together so that when we have learning collaboratives, not only do we have learning collaboratives within each of these spheres, but we learn from each other in these similar projects, said Peter Aran, MD, medical director of Population Health Management at Blue Cross Blue Shield of Oklahoma.

$Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM$

January 22nd 2018

Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM

Laura Joszt, MA

The FDA has approved a supplemental New Drug Application to add new overall survival (OS) data for carfilzomib (Kyprolis). The label will now show that carfilzomib and dexamethasone reduced the risk of death by 21% and increased OS by 7.6 months compared with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (MM).

January 22nd 2018

The Fallacy of Estimating OCM Target Prices

Darcie Hurteau

Estimating episodic target prices for each patient in the Oncology Care Model (OCM) can be challenging and time consuming. Applying that time to quality-focused care management tactics, based on observed utilization and patient outcomes, may wind up being more valuable, and help to reduce unnecessary spending.

January 20th 2018

Treating Patients With Melanoma With Targeted Therapies Before Surgery Can Delay Relapse

Samantha DiGrande

Researchers at The University of Texas MD Anderson Cancer Center recently reported in Lancet Oncology that a pair of targeted therapies given before and after surgery for melanoma produced a 6-fold increase in time to progression of the disease, compared with standard-of-care surgery for patients with stage 3 melanoma.

...

56 57 58 59 60 61 62 63 64

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions